Alcon Fails to Undo $34 Million Patent Loss, Must Pay Royalties

Alcon Inc. failed to overturn a $34 million patent verdict over its minimally invasive glaucoma device, as a federal judge upheld a Delaware jury’s infringement and validity findings.

Judge Jennifer L. Hall denied Alcon’s post-trial bid for judgment as a matter of law or a new trial and rejected patent owner Sight Sciences Inc.’s request to block future sales, instead imposing a 10% ongoing royalty on revenue from Alcon’s Hydrus Microstent.

Hall’s opinion, issued March 27 in the US District Court for the District of Delaware, preserves a jury’s April 2024 findings that the Hydrus Microstent—including its delivery system, ...